Stability and performance of a population pharmacokinetic model.
about
Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic studyPopulation pharmacokinetics of bevacizumab in cancer patients with external validationFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionEfficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infectionThe process of knowledge discovery from large pharmacokinetic data sets.New generalized poisson mixture model for bimodal count data with drug effect: An application to rodent brief-access taste aversion experiments.Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureusPredicting the time course of haemoglobin in children treated with erythropoietin for renal anaemiaPopulation pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjectsPopulation pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patientsMeropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Time-dependent clearance of mycophenolic acid in renal transplant recipientsPopulation pharmacokinetics of darbepoetin alfa in healthy subjectsPopulation pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administrationValidation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.Population pharmacokinetics/pharmacodynamics of anestheticsA d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor VismodegibPopulation pharmacokinetics and optimization of the dosing regimen of digoxin in adult patientsPopulation pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.Population pharmacokinetic analysis and dosing regimen optimization of penicillin G in patients with infective endocarditis.Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.
P2860
Q24679028-6102EA69-3158-411F-86EB-9E6F34E1AC95Q26779580-5994BF5B-5533-41B1-A7E9-54485DD69BCDQ28475976-62899063-BBFC-4E49-9BC8-1F93C567A281Q30408582-16801BA7-E06B-433D-A4F9-F63377C8813BQ30623903-68D6D53B-4F77-497E-8EF6-AC852B4A791BQ31118425-D1211ABF-1B6C-48FD-963C-2492B3A8B6E8Q33364134-566773B2-C758-414A-AD59-9E072DDFE307Q33487458-CDEA7919-9A21-46AF-8FCB-2A71A4F38039Q33524423-E1366A68-8619-48A9-BDA7-DAC50B9BCFE0Q33605816-648759E1-B3BE-402C-BAA4-B19CD4D5CC50Q33826426-05E1549A-2A11-45CF-9C84-803C168BCA0DQ33954595-20264A43-145D-4C4D-8ABF-FC4FD485208DQ34123784-B11A3ACE-4358-47CE-A829-C5FE55D1C763Q35127932-70A88F91-486C-4AE1-A264-C56ACDDF14BEQ35802641-1F4BA193-29FD-4A33-AF70-0580094B95ECQ35825455-826AA078-C9CA-455C-9E93-DADA34B18AC0Q35825778-452B8F62-DD6C-4AD0-A0D4-404F7AE98184Q35827262-85E842BF-DDC5-454B-BA1B-9036801D74E8Q35912649-9B3B12C1-C202-4C66-B8A1-778F15A30918Q35928858-09703499-89F5-483B-B712-38DA2D321342Q35937040-04238B12-83FB-4BD2-80F7-B3E057A3B626Q35960694-83EF12BC-A6E2-4527-B53A-C1E55EC49273Q35960882-4216B459-115B-43D8-9F1A-4972AAB29DD4Q36024478-AC4CE419-797F-4A09-86CA-E3F8B2D769ABQ36024876-9C5F9287-D697-4F75-BA8D-71661E1D61EFQ36025060-89DF4154-C01C-462D-910E-AD5C2D2ABF10Q36053921-47079BBF-32AD-4CB8-A487-232DFDB50EBFQ36111207-6EE8DFB2-8430-40F5-94F3-4D43480DEEFBQ36125427-AAD44D96-45D1-4F16-B2C0-535643854EB7Q36172421-9A22ED95-62F9-449F-B32D-3A8E7E3E209BQ36233555-4E427BD8-92A6-4AEE-AAD6-AC9DC539DC8DQ36341601-D8E51A7E-9C69-4403-BD4B-AB2F9015CFC7Q36388027-AAF3B661-60F5-4130-8447-C4547762E562Q36410210-464B5D6A-50CA-4513-9276-E1DAAF4700E8Q36473104-03EA595F-D157-410B-93EF-DE15D19057CFQ36508024-781B0590-466E-483D-9127-B240D2881D5FQ36609716-10136D4D-D996-4E79-A793-D13EB35494DCQ36747438-29B241BF-1B6F-4F95-BE1A-BB92B6321E6BQ36765434-7FCF7EE6-20CC-4EC7-AA49-4CDA0E6FB8D0Q36801536-4168718A-31BC-40F6-8DA7-FE68ECBA504F
P2860
Stability and performance of a population pharmacokinetic model.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Stability and performance of a population pharmacokinetic model.
@en
Stability and performance of a population pharmacokinetic model.
@nl
type
label
Stability and performance of a population pharmacokinetic model.
@en
Stability and performance of a population pharmacokinetic model.
@nl
prefLabel
Stability and performance of a population pharmacokinetic model.
@en
Stability and performance of a population pharmacokinetic model.
@nl
P1476
Stability and performance of a population pharmacokinetic model.
@en
P2093
P2860
P304
P356
10.1002/J.1552-4604.1997.TB04326.X
P577
1997-06-01T00:00:00Z